HSIC — Henry Schein, Inc.
NASDAQ
Q1 2026 Earnings Call Summary
May 5, 2026
Summary of Henry Schein's Q1 2026 Earnings Call
1. Key Financial Results and Metrics
- Global Sales: $3.4 billion, up 6.3% year-over-year.
- GAAP Operating Margin: 5.41%, down 12 basis points from the previous year.
- Non-GAAP Operating Margin: 7.53%, up 28 basis points, driven by gross margin expansion.
- GAAP Net Income: $107 million ($0.92 per diluted share), compared to $110 million ($0.88 per diluted share) in Q1 2025.
- Non-GAAP Net Income: $153 million ($1.32 per diluted share), up from $143 million ($1.15 per diluted share) in the prior year.
- Adjusted EBITDA: $289 million, an 11.6% increase from $259 million in Q1 2025.
- Operating Cash Flow: Negative $97 million due to seasonal decreases in accounts payable.
2. Strategic Updates and Business Highlights
- BOLD+1 Strategy: Focus on enhancing operational execution and integrating technology to improve customer experience and efficiency.
- Market Position: Strong competitive advantages in the dental market, with ongoing investments from Dental Service Organizations (DSOs) driving growth.
- Product Development: Increased focus on AI solutions and technology integration, with successful launches at recent events.
- Value Creation Initiatives: Targeting over $200 million in annual operating income improvement, with a $125 million run rate expected by the end of 2026.
- E-commerce Expansion: Successful rollout of the global e-commerce platform, with over 80% of U.S. dental e-commerce sales now transacted online.
3. Forward Guidance and Outlook
- 2026 Financial Guidance:
- Total sales growth expected to be approximately 3% to 5%.
- Non-GAAP diluted EPS projected between $5.23 and $5.37.
- Adjusted EBITDA anticipated to grow in the mid-single digits.
- Guidance assumes stable dental and medical end markets and mitigated impacts from rising oil prices.
4. Challenges and Points of Concern
- Medical Business Softness: Decline in demand for point-of-care diagnostic products due to a light flu season, impacting overall medical sales.
- Rising Costs: Concerns about increasing oil prices affecting freight and product costs, although management is implementing measures to mitigate these impacts.
- Market Dynamics: Competitive pressures from lower-priced entrants in the digital equipment market, which may affect margins.
5. Notable Q&A Insights
- Gross Margin Drivers: Improvements attributed to value creation initiatives and a dynamic pricing environment, with own brand products outpacing overall portfolio growth.
- Specialty Products Growth: Expected to improve in subsequent quarters, with strong demand for value implants but flat performance in premium implants.
- DSO Growth: DSOs are growing faster than the overall market, with Henry Schein positioned as a key partner due to its comprehensive support and technology offerings.
- Customer Engagement: Management emphasizes the importance of maintaining strong relationships with customers, particularly when discussing price increases due to rising costs.
Overall, Henry Schein reported a strong start to 2026, with solid sales growth and strategic initiatives aimed at enhancing operational efficiency and customer service, despite facing challenges in the medical segment and rising costs.
